Adverum Biotechnologies (ADVM) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: anniversary, appeal, Ataxia, bank, cap, cardiomyopathy, Carolina, center, certainty, companion, composed, content, correspondingly, cybersecurity, degradation, deposit, detract, diagnostic, Durham, Excellence, Exhibit, expiry, FDIC, floor, Foundation, Friedreich, furniture, gather, hacktivist, harvesting, honor, ILAP, infer, Innovation, Innovative, JAGUAR, jointly, kickoff, knowhow, landlord, lawfully, leasehold, letter, line, MHRA, micro, NC, North, opposed, opting, outlining, Panel, Passport, Pathway, poorly, portion, reevaluating, REGION, regional, relocate, remeasurement, represent, retrospective, revalued, rigor, roadmap, route, sample, senior, shipping, Silicon, split, step, subsidiary, suitable, SVB, tenant, undiscounted, unitary, UPC, Valley, vascular, wiretapping, write

Removed: abroad, absent, absolute, accessed, accident, affording, Annapurna, begun, bioanalytical, collecting, complicating, conceived, contest, contracting, Cornell, CRO, departure, deteriorate, disrupted, economically, endeavor, ending, essential, exacerbate, expanded, expansion, exploitable, facilitate, fear, globally, Graybug, impaired, initiating, Kodiak, landscape, loan, lodge, lost, LUXTURNA, mechanism, met, operative, Opthea, planning, pool, posture, procuring, proxy, renewed, repayment, repeated, residency, resource, retaining, retention, scheduled, sequester, slower, space, staffing, steroid, stolen, stored, supervisory, Switzerland, unilaterally, upfront, Utah, vital, withdrawn, ZOLGENSMA

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ADVM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Linda Rubinstein, in her capacity as Chief Financial Officer, of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.


Date:	May 11, 2023	By:	/s/ Linda Rubinstein
			Linda Rubinstein
			Chief Financial Officer
			(Principal Financial Officer and Principal Accounting Officer)